New drug combo aims to shrink rectal tumors before surgery
NCT ID NCT07528209
First seen Apr 24, 2026 · Last updated Apr 24, 2026
Summary
This study tests whether adding an immunotherapy drug (pucotenlimab) to standard chemotherapy (CAPOX) helps shrink tumors more effectively in people with locally advanced rectal cancer. About 556 adults aged 18-75 will be randomly assigned to receive either the drug combo or chemo alone, with some also getting short-course radiation if needed. The goal is to improve the chance of being cancer-free 3 years after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.